Operational updates
Pharming announces publication of RUCONEST® prophylactic data in The Lancet
Pharming Group N.V. today announced The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical trial (NCT02247739) evaluating the efficacy and safety of RUCONEST® (C1 esterase inhibitor [recombinant]) for the prevention of hereditary angioedema (HAE) attacks.
“We wish to thank the patients and researchers involved in this study, and we look forward to continuing our work with the HAE community to improve treatment options.”
- Bruno Giannetti - COO